Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00885742 · ClinicalTrials.gov registry record · Phase 3
A Study of Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency
A Phase 3 study, sponsored by CSL Behring.
- Completed
- Registry status
- Phase 3
- Development phase
- 41
- Enrollment target
NCT00885742: Completed Phase 3 study, sponsored by CSL Behring.
NCT00885742 is a Phase 3 study that has completed, run by CSL Behring. The registered enrollment target is 41 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00885742, a Phase 3 study, has completed, sponsored by CSL Behring.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 41 participants
- Enrollment target
Study Summary
Congenital deficiency of factor XIII (FXIII) is an extremely rare inherited disorder associated with potentially life-threatening bleeding. Factor XIII Concentrate is given to patients whose blood is lacking factor XIII. Factor XIII Concentrate works by assisting blood in the usual clotting process, thereby preventing bleeding. In this study, patients will be treated with FXIII Concentrate (Human) and followed closely to determine that they receive the dose that will best minimize the chance of bruising and bleeding.
Primary Outcome
The number of subjects requiring treatment with a Factor XIII-containing product to treat a spontaneous bleeding event.
Interventions
- BIOLOGICAL FXIII Concentrate (Human)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2009-08 |
| Est. Completion | 2011-04 |
| Phase | Phase 3 |
What the finished NCT00885742 record still lists
NCT00885742 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 41 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 1 intervention - of which FXIII Concentrate (Human) is the first listed.
NCT00885742 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00885742 about?
NCT00885742 is a clinical study titled "A Study of Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency". Congenital deficiency of factor XIII (FXIII) is an extremely rare inherited disorder associated with potentially life-threatening bleeding. Factor XIII Concentrate is given to patients whose blood is lacking factor XIII. Factor XIII Concentrate works by assisting blood in the usual clotting process,...
What is the current status of trial NCT00885742?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 41 participants. The study started on 2009-08. Estimated completion is 2011-04.
What interventions are being tested in trial NCT00885742?
The interventions under investigation include: FXIII Concentrate (Human) (BIOLOGICAL).
Who is sponsoring clinical trial NCT00885742?
This trial is sponsored by CSL Behring, which has 71 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00885742's enrollment target sits among peer trials
41 1877th of 2000 higher than 123 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03449238 · 41 participants · Phase 1
Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients
- NCT03900793 · 41 participants · Phase 1
Losartan + Sunitinib in Treatment of Osteosarcoma
- NCT04082520 · 41 participants · Phase 2
Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy
- NCT04220190 · 41 participants · Phase 2
RAPA-501 Therapy for ALS
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia